Clinical Trials | January 24, 2022
RaphaCure partners with Madhavbaug for cardiac healthcare services
Madhavbaug has a pan-India presence with a vast network of 272 clinics and two hospitals
Madhavbaug has a pan-India presence with a vast network of 272 clinics and two hospitals
APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types
Al-Futtaim will utilize TytoCare's TytoPro system in outpatient clinics around Dubai, providing patients with enhanced care and better access to specialists
Go-ahead for pivotal clinical trial which is expected to commence by March
Omicron patients below 60 with no comorbidities can start treatment with paracetamol
Pfizer is evaluating the FDA’s comments and will work with the agency to determine an appropriate path forward
The appointment is key for DefiniGEN as they expand the service portfolio to encompass compound screening
The drug is to be supplied in 105 low and middle-income countries and 10 Indian firms are on the list
It is the first CAR T Therapy approved for the treatment of multiple myeloma in Japan
Phase 1/2 trial of E-602 expected to open in Q1 2022 in patients with solid tumours
Subscribe To Our Newsletter & Stay Updated
